60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia. Show more

1025 Connecticut Avenue NW, Washington, DC, 20036, United States

Biotechnology
Healthcare

Market Cap

3.665M

52 Wk Range

$1.29 - $14.68

Previous Close

$1.46

Open

$1.48

Volume

23,286

Day Range

$1.39 - $1.48

Enterprise Value

12.24M

Cash

1.51M

Avg Qtr Burn

-1.692M

Insider Ownership

1.21%

Institutional Own.

9.68%

Qtr Updated

12/31/25